Skip to main content
. Author manuscript; available in PMC: 2009 Jan 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2007 Mar 29;61(1):133–144. doi: 10.1007/s00280-007-0458-z

Fig. 5.

Fig. 5

Tissue to plasma ratios (Kp) measured at 24 h post-IV administration of control rapamycin (open square), rapamycin in PEG-b-PCL (dotted rectangle), and rapamycin in PEG-b-PCL + α-tocopherol formulation (filled square) (10 mg/kg) to rats (mean ± SEM, n = 4 per group). *Denotes statistical significant difference (P < 0.05) between control and formulation. #Denotes statistical significant difference (P < 0.05) between both formulations